Engagement of signaling pathways of protease-activated receptor 2 and μ-opioid receptor in bone cancer pain and morphine tolerance

International Journal of Cancer

Volumn 137, Issue 6, 2015, Pages 1475-1483

  Bao, Yanju ^a   Gao, Yebo ^a,b   Hou, Wei ^a   Yang, Liping ^a   Kong, Xiangying ^a   Zheng, Honggang ^a   Li, Conghuang ^a   Hua, Baojin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MORPHINE; MU OPIATE RECEPTOR; PHENYLALANYLSERYLLEUCYLLEUCYLARGINYLTYROSINE AMIDE; PROTEIN KINASE C EPSILON; PROTEINASE ACTIVATED RECEPTOR 2; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; PROTEIN KINASE C; PROTEIN KINASE C ZETA; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BONE CANCER; CANCER CELL LINE; CANCER PAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERANCE; ENZYME ACTIVITY; FEMALE; HYPERALGESIA; MALE; MECHANICAL HYPERALGESIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN; THERMAL HYPERALGESIA; TIBIA; ANIMAL; BONE TUMOR; BREAST TUMOR; CARCINOMA; COMPLICATION; DRUG EFFECTS; METABOLISM; PAIN; WISTAR RAT;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA 256, WALKER; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; HYPERALGESIA; MALE; MORPHINE; PAIN; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTOR, PAR-2; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN; TRPV CATION CHANNELS;

EID: 84936845702     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29497     Document Type: Article

References (35)

1. Hanna M, Zylicz Z (Ben),. Cancer pain. London: Springer, 2013. vii & 17.
2. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al., Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-49.
3. Urch CE, Suzuki R., Pathophysiology of somatic, visceral, and neuropathic cancer pain. In:, Sykes N, Bennett MI, Yuan C-S, eds. Clinical pain management: cancer pain. London: Hodder Arnold, 2008. 3-12.
4. Mantyh P,. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 2013; 154: S54-62.
5. Schug SA, Auret K., Clinical pharmacology: principles of analgesic drug management. In:, Sykes N, Bennett MI, Yuan C-S, eds. Clinical pain management: cancer pain. London: Hodder Arnold, 2008. 104-22.
6. Bao Y, Hou W, Hua B,. Protease-activated receptor 2 signalling pathways: a role in pain processing. Expert Opin Ther Targets 2014; 18: 15-27.
7. Bao Y, Hou W, Kong X, et al., Hydromorphone for cancer pain. Cochrane Database Syst Rev 2014; 5: 1-7.
8. Bao Y, Kong X, Yang L, et al., Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Altern Med 2014; 2014: 170396.
9. Futakuchi M, Singh RK,. Animal model for mammary tumor growth in the bone microenvironment. Breast Cancer 2013; 20: 195-203.
10. Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW,. Cancer-induced bone pain: mechanisms and models. Neurosci Lett 2013; 557: 52-9.
11. Bao Y, Hou W, Liu R, et al., PAR2-mediated upregulation of BDNF contributes to central sensitization in bone cancer pain. Mol Pain 2014; 10: 28.
12. Bao Y, Hou W, Yang L, et al., Increased expression of protease-activated receptor 2 and 4 within dorsal root ganglia in a rat model of bone cancer pain. J Mol Neurosci 2015; 55: 706-14.
13. Bao Y, Hua B, Hou W, et al., Involvement of protease-activated receptor 2 in nociceptive behavior in a rat model of bone cancer. J Mol Neurosci 2014; 52: 566-76.
14. Yamamoto J, Kawamata T, Niiyama Y, et al., Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 2008; 151: 843-53.
15. Chaplan SR, Bach FW, Pogrel JW, et al., Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63.
16. Chen Y, Yang C, Wang ZJ,. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011; 193: 440-51.
17. Ju J, Shin DJ, Na YC, et al., Role of spinal opioid receptor on the antiallodynic effect of intrathecal nociceptin in neuropathic rat. Neurosci Lett 2013; 542: 118-22.
18. Uchytilova E, Spicarova D, Palecek J,. TRPV1 antagonist attenuates postoperative hypersensitivity by central and peripheral mechanisms. Mol Pain 2014; 10: 67.
19. Cottrell GS, Amadesi S, Schmidlin F, et al., Protease-activated receptor 2: activation, signalling and function. Biochem Soc Trans 2003; 31: 1191-7.
20. D'Andrea MR, Derian CK, Leturcq D, et al., Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem 1998; 46: 157-64.
21. Steinhoff M, Vergnolle N, Young SH, et al., Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6: 151-8.
22. Alier KA, Endicott JA, Stemkowski PL, et al., Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther 2008; 324: 224-33.
23. Vergnolle N, Bunnett NW, Sharkey KA, et al., Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 2001; 7: 821-6.
24. Morgado C, Terra PP, Tavares I,. Neuronal hyperactivity at the spinal cord and periaqueductal grey during painful diabetic neuropathy: effects of gabapentin. Eur J Pain 2010; 14: 693-9.
25. Silva M, Amorim D, Almeida A, et al., Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain modulatory cells in the streptozotocin-diabetic rat. Brain Res Bull 2013; 96: 39-44.
26. Bouhassira D, Lantéri-Minet M, Attal N, et al., Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008; 136: 380-7.
27. Hua X-Y, Yaksh TL., Dorsal horn substance P and NK1 receptors: study of a model system in spinal nociceptive processing. In:, Malcangio M,. Synaptic plasticity in pain. London: Springer Science Business Media, 2009. 109-38.
28. Spahn V, Fischer O, Endres-Becker J, et al., Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase a-dependent manner. Pain 2013; 154: 598-608.
29. Caterina MJ, Leffler A, Malmberg AB, et al., Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288: 306-13.
30. Caterina MJ, Schumacher MA, Tominaga M, et al., The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
31. Davis JB, Gray J, Gunthorpe MJ, et al., Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-7.
32. Niiyama Y, Kawamata T, Yamamoto J, et al., Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 2007; 148: 560-72.
33. Amadesi S, Cottrell GS, Divino L, et al., Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and a-dependent mechanisms in rats and mice. J Physiol 2006; 575: 555-71.
34. Dai Y, Moriyama T, Higashi T, et al., Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. J Neurosci 2004; 24: 4293-9.
35. Vriens J, Appendino G, Nilius B,. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009; 75: 1262-79.